Clinical trial · Observational
Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy
Risk Factors for Recurrence and Survival Outcomes of Esophageal Squamous Cell Carcinoma Patients with Complete Pathological Response After Neoadjuvant Therapy：A Multicenter Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Esophageal cancer is one of the most common malignant tumors worldwide, with high invasiveness and lethality. Currently, the treatment for resectable locally advanced esophageal cancer mainly consists of a treatment model centered on surgical treatment with the participation of multiple disciplines. Neoadjuvant treatment regimens include chemotherapy, chemoradiotherapy, and chemotherapy combined with immunotherapy. Complete pathological response (pCR)is currently regarded as one of the important indicators for evaluating the efficacy of neoadjuvant treatment. Previous studies have shown that 14%-39% of patients with complete pathological response after neoadjuvant treatment still experience recurrence and metastasis within two years after surgery, suggesting that pCR after esophageal cancer surgery does not mean clinical cure. Perhaps there is a highly risk clinical subgroup need to research. Therefore, based on the prospective clinical database of the National Cancer Center and in cooperation with multiple national cancer regional medical centers, this study analyzes and explores the prognosis of patients with locally advanced esophageal squamous cell carcinoma with pCR after neoadjuvant treatment, characterized by the Chinese population.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Neoadjuvant therapy with PD-L1 inhibitor | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Recurrence
- description
- Patients with complete pathological response after neoadjuvant treatment experience recurrence or metastasis after surgery
- interventionNames
- Procedure: Neoadjuvant therapy with PD-L1 inhibitor
- label
- Non-recurrence
- description
- Patients with complete pathological response after neoadjuvant treatment without recurrence or metastasis after surgery
- interventionNames
- Procedure: Neoadjuvant therapy with PD-L1 inhibitor
Primary outcomes (1)
- measure
- Disease-Free Survival
- timeFrame
- The postoperative follow-up period should last for at least one year.
- description
- The time from the postoperative period of the patient to the first occurrence of recurrence or metastasis.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Patients treated neoadjvant treatment followed by esophagectomy from 2018 to 2023 * Patients with thoracic esophageal squamous cell carcinoma * The preoperative clnical stage is cT1N+M0/cT2-4aN0-3M0, with potential resectability * Patients with complete pathological response (ypT0N0M0) * Without distant metastasis was found in the preoperative examinations, and the tumor did not directly invade the pancreas, spleen, trachea, aorta or other adjacent organs such as the lungs Exclusion Criteria: * Patients with previous history of malignant tumors * Patients with multiple primary cancers * Deficient neoadjuvant treatment or salvage surgery * Incomplete clinical data
References
Publications (0)
Data not yet available